90 related articles for article (PubMed ID: 18773877)
1. Intracellular metabolism of the new antiviral compound 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine.
Naesens L; Andrei G; Votruba I; Krecmerová M; Holý A; Neyts J; De Clercq E; Snoeck R
Biochem Pharmacol; 2008 Oct; 76(8):997-1005. PubMed ID: 18773877
[TBL] [Abstract][Full Text] [Related]
2. N(4)-Acyl derivatives as lipophilic prodrugs of cidofovir and its 5-azacytosine analogue, (S)-HPMP-5-azaC: chemistry and antiviral activity.
Krečmerová M; Pohl R; Masojídková M; Balzarini J; Snoeck R; Andrei G
Bioorg Med Chem; 2014 May; 22(10):2896-906. PubMed ID: 24731540
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of novel acyclic nucleoside phosphonates against human and animal gammaherpesviruses revealed an altered metabolism of cyclic prodrugs upon Epstein-Barr virus reactivation in P3HR-1 cells.
Coen N; Duraffour S; Naesens L; Krecmerová M; Van den Oord J; Snoeck R; Andrei G
J Virol; 2013 Nov; 87(22):12422-32. PubMed ID: 24027315
[TBL] [Abstract][Full Text] [Related]
4. Acyclic nucleoside phosphonates with 5-azacytosine base moiety substituted in C-6 position.
Krecmerová M; Masojídková M; Holý A
Bioorg Med Chem; 2010 Jan; 18(1):387-95. PubMed ID: 19914075
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic potential of Cidofovir (HPMPC, Vistide) for the treatment of DNA virus (i.e. herpes-, papova-, pox- and adenovirus) infections.
De Clercq E
Verh K Acad Geneeskd Belg; 1996; 58(1):19-47; discussion 47-9. PubMed ID: 8701600
[TBL] [Abstract][Full Text] [Related]
6. Antiviral activity of triazine analogues of 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine (cidofovir) and related compounds.
Krecmerová M; Holý A; Pískala A; Masojídková M; Andrei G; Naesens L; Neyts J; Balzarini J; De Clercq E; Snoeck R
J Med Chem; 2007 Mar; 50(5):1069-77. PubMed ID: 17298047
[TBL] [Abstract][Full Text] [Related]
7. Activities of different classes of acyclic nucleoside phosphonates against BK virus in primary human renal cells.
Topalis D; Lebeau I; Krecmerová M; Andrei G; Snoeck R
Antimicrob Agents Chemother; 2011 May; 55(5):1961-7. PubMed ID: 21343444
[TBL] [Abstract][Full Text] [Related]
8. DNA polymerase mutations in drug-resistant herpes simplex virus mutants determine in vivo neurovirulence and drug-enzyme interactions.
Andrei G; Fiten P; Froeyen M; De Clercq E; Opdenakker G; Snoeck R
Antivir Ther; 2007; 12(5):719-32. PubMed ID: 17713155
[TBL] [Abstract][Full Text] [Related]
9. Metabolic diversity and antiviral activities of acyclic nucleoside phosphonates.
Aduma P; Connelly MC; Srinivas RV; Fridland A
Mol Pharmacol; 1995 Apr; 47(4):816-22. PubMed ID: 7723743
[TBL] [Abstract][Full Text] [Related]
10. The antiviral activity and mechanism of action of (S)-[3-hydroxy-2-(phosphonomethoxy)propyl] (HPMP) nucleosides.
Magee WC; Evans DH
Antiviral Res; 2012 Nov; 96(2):169-80. PubMed ID: 22960154
[TBL] [Abstract][Full Text] [Related]
11. Intracellular metabolism of the antiherpes agent (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine.
Ho HT; Woods KL; Bronson JJ; De Boeck H; Martin JC; Hitchcock MJ
Mol Pharmacol; 1992 Jan; 41(1):197-202. PubMed ID: 1310143
[TBL] [Abstract][Full Text] [Related]
12. Study of chemical stability of antivirally active 5-azacytosine acyclic nucleoside phosphonates using NMR spectroscopy.
Dracínský M; Krecmerová M; Holý A
Bioorg Med Chem; 2008 Jul; 16(14):6778-82. PubMed ID: 18554916
[TBL] [Abstract][Full Text] [Related]
13. New prodrugs of two pyrimidine acyclic nucleoside phosphonates: Synthesis and antiviral activity.
Krečmerová M; Dračínský M; Snoeck R; Balzarini J; Pomeisl K; Andrei G
Bioorg Med Chem; 2017 Sep; 25(17):4637-4648. PubMed ID: 28757102
[TBL] [Abstract][Full Text] [Related]
14. Identification of enzymes catalyzing two-step phosphorylation of cidofovir and the effect of cytomegalovirus infection on their activities in host cells.
Cihlar T; Chen MS
Mol Pharmacol; 1996 Dec; 50(6):1502-10. PubMed ID: 8967971
[TBL] [Abstract][Full Text] [Related]
15. Activities of several classes of acyclic nucleoside phosphonates against camelpox virus replication in different cell culture models.
Duraffour S; Snoeck R; Krecmerová M; van Den Oord J; De Vos R; Holy A; Crance JM; Garin D; De Clercq E; Andrei G
Antimicrob Agents Chemother; 2007 Dec; 51(12):4410-9. PubMed ID: 17893157
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics, bioavailability, metabolism, and tissue distribution of cidofovir (HPMPC) and cyclic HPMPC in rats.
Cundy KC; Bidgood AM; Lynch G; Shaw JP; Griffin L; Lee WA
Drug Metab Dispos; 1996 Jul; 24(7):745-52. PubMed ID: 8818571
[TBL] [Abstract][Full Text] [Related]
17. Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity.
Krecmerová M; Holý A; Pohl R; Masojídková M; Andrei G; Naesens L; Neyts J; Balzarini J; De Clercq E; Snoeck R
J Med Chem; 2007 Nov; 50(23):5765-72. PubMed ID: 17948980
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of HIV-1 by octadecyloxyethyl esters of (S)-[3-hydroxy-2-(phosphonomethoxy)propyl] nucleosides and evaluation of their mechanism of action.
Magee WC; Valiaeva N; Beadle JR; Richman DD; Hostetler KY; Evans DH
Antimicrob Agents Chemother; 2011 Nov; 55(11):5063-72. PubMed ID: 21896914
[TBL] [Abstract][Full Text] [Related]
19. Antiviral evaluation of octadecyloxyethyl esters of (S)-3-hydroxy-2-(phosphonomethoxy)propyl nucleosides against herpesviruses and orthopoxviruses.
Valiaeva N; Prichard MN; Buller RM; Beadle JR; Hartline CB; Keith KA; Schriewer J; Trahan J; Hostetler KY
Antiviral Res; 2009 Dec; 84(3):254-9. PubMed ID: 19800369
[TBL] [Abstract][Full Text] [Related]
20. (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) inhibits HIV-1 replication in epithelial cells, but not T-lymphocytes.
Srinivas RV; Connely M; Fridland A
Antiviral Res; 1997 Jun; 35(1):23-7. PubMed ID: 9224958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
